MX2017003251A - Uso antibacteriano de salicilanilidas halogenadas. - Google Patents

Uso antibacteriano de salicilanilidas halogenadas.

Info

Publication number
MX2017003251A
MX2017003251A MX2017003251A MX2017003251A MX2017003251A MX 2017003251 A MX2017003251 A MX 2017003251A MX 2017003251 A MX2017003251 A MX 2017003251A MX 2017003251 A MX2017003251 A MX 2017003251A MX 2017003251 A MX2017003251 A MX 2017003251A
Authority
MX
Mexico
Prior art keywords
positive bacteria
halogenated salicylanilides
halogenated
gram
antibacterial use
Prior art date
Application number
MX2017003251A
Other languages
English (en)
Inventor
Flora Aurore DELAVENNE Emilie
Jean Jacques Simon Daniel
otto alexander sommer Morten
Vendler Toft Kehler Rasmus
Original Assignee
Antibiotx Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antibiotx Aps filed Critical Antibiotx Aps
Publication of MX2017003251A publication Critical patent/MX2017003251A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una salicilanilida halogenada seleccionada de closantel, rafoxanida, oxiclozanida y niclosamida y derivados de las mismas incluyendo sales, hidratos, ésteres y similares, para su uso en el tratamiento tópico o la prevención de infecciones causadas por bacterias Gram-positivas tales como Staphylococcus, en particular Staphylococcus aureus, y Streptococcus, en particular, Streptococcus pyogenes; las bacterias Gram positivas tratadas con las salicilanilidas halogenadas exhiben una frecuencia muy baja de aparición de mutantes resistentes en comparación con los antibióticos tópicos usados comúnmente.
MX2017003251A 2014-09-12 2015-09-08 Uso antibacteriano de salicilanilidas halogenadas. MX2017003251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1451054 2014-09-12
PCT/EP2015/070495 WO2016038035A1 (en) 2014-09-12 2015-09-08 Antibacterial use of halogenated salicylanilides

Publications (1)

Publication Number Publication Date
MX2017003251A true MX2017003251A (es) 2017-12-20

Family

ID=54072831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003251A MX2017003251A (es) 2014-09-12 2015-09-08 Uso antibacteriano de salicilanilidas halogenadas.

Country Status (19)

Country Link
US (6) US20170258816A1 (es)
EP (3) EP3967312A1 (es)
JP (3) JP2017529393A (es)
KR (1) KR20170078600A (es)
CN (1) CN106999505A (es)
AU (1) AU2015314287B2 (es)
BR (1) BR112017004889A2 (es)
CA (1) CA2960331A1 (es)
DK (1) DK3010511T3 (es)
EA (1) EA032899B1 (es)
ES (2) ES2970434T3 (es)
HK (1) HK1223277A1 (es)
IL (1) IL250988A0 (es)
MX (1) MX2017003251A (es)
PH (1) PH12017500463B1 (es)
PL (1) PL3010511T3 (es)
SG (1) SG11201701928RA (es)
TR (1) TR201802762T4 (es)
WO (1) WO2016038035A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170258816A1 (en) 2014-09-12 2017-09-14 Antibiotx Aps Antibacterial Use of Halogenated Salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US10792272B2 (en) 2016-07-15 2020-10-06 The Scripps Research Institute Methods for treatment of Clostridium difficile infections
GB201615693D0 (en) 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations
CA3057284A1 (en) * 2017-03-21 2018-09-27 Novalead Pharma Inc. Therapeutic agent for phosphodiesterase inhibition and its related disorders
EP3403652A1 (en) 2017-05-18 2018-11-21 Veterinärmedizinische Universität Wien Prevention and treatment of fibroblast growth factor 23 (fgf23)-associated disorders including chronic kidney disease (ckd)
GB201713653D0 (en) * 2017-08-24 2017-10-11 Antibiotx As Dosage regimen
JP2020533417A (ja) * 2017-09-15 2020-11-19 セバ・サンテ・アニマル 抗菌組成物
GB201805453D0 (en) * 2018-04-03 2018-05-16 Antibiotx As Novel use
EP3793539A4 (en) * 2018-05-15 2022-03-02 Dana-Farber Cancer Institute, Inc. COMPOUNDS FOR THE TREATMENT OF DENGUE VIRUS INFECTIONS AND OTHER INFECTIONS
GB201813876D0 (en) 2018-08-24 2018-10-10 Antibiotx As Treatment
US10995061B2 (en) 2018-10-02 2021-05-04 United States Government As Represented By The Department Of Veterans Affairs SPAK kinase inhibitors as neuroprotective agents
CA3118172A1 (en) * 2018-11-02 2020-05-07 UNION therapeutics A/S Halogenated salicylanilides for treating the symptoms of dermatitis
WO2020089467A1 (en) 2018-11-02 2020-05-07 UNION therapeutics A/S Dosage regimen
CN109331025A (zh) * 2018-11-22 2019-02-15 华中农业大学 羟氯扎胺在制备抗猪链球菌的药物中的应用
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
WO2020176067A1 (en) 2019-02-25 2020-09-03 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with h. pylori using a halogenated salicylanilide
CN111150725A (zh) * 2019-10-31 2020-05-15 天津国际生物医药联合研究院 氯氰碘柳胺钠在抗分枝杆菌感染中的潜在应用
WO2021168295A1 (en) * 2020-02-21 2021-08-26 Yourchoice Therapeutics, Inc. Use of nicolsamide formulations for antiviral therapy
EP4125804A1 (en) 2020-04-01 2023-02-08 UNION therapeutics A/S Treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
JP2023520229A (ja) 2020-04-01 2023-05-16 ユニオン・セラピューティクス・アー／エス 製剤
WO2022076565A1 (en) 2020-10-07 2022-04-14 Sorrento Therapeutics, Inc. Salicylanilide analogs for use in the treatment of coronavirus
GB202102488D0 (en) 2021-02-22 2021-04-07 Union Therapeutics As Treatment
US11925611B2 (en) 2021-03-26 2024-03-12 United States Government As Represented By The Department Of Veterans Affairs Use of ZT-1A and analogs thereof to prevent and/or treat neurodegenerative and neurocognitive disorders
CN117105809B (zh) * 2023-10-20 2024-05-03 中国农业大学 一种苯甲酰苯胺化合物及其制备方法和应用

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731386A (en) 1951-09-06 1956-01-17 Wallace & Tiernan Company Inc Antifungal composition
US3152039A (en) 1960-11-23 1964-10-06 Dow Chemical Co Germicidal compositions
FR1340175A (fr) 1962-03-06 1963-10-18 Procter & Gamble Nouvelles compositions bactéricides
DE1527638C3 (de) 1966-06-15 1974-01-31 Gesellschaft Zur Foerderung Der Eisenhuettentechnik Mbh, 4000 Duesseldorf Vorrichtung zum Kanten und Verschieben von Walzgut (Blöcken, Brammen u.dgl.) auf Rollgängen in Walzwerken
US3674850A (en) * 1969-12-07 1972-07-04 Lever Brothers Ltd Substituted salicylanilides
US3914418A (en) * 1971-09-02 1975-10-21 Merck & Co Inc Methods of controlling liver fluke infections
GB1421589A (en) 1972-03-07 1976-01-21 Janssen Pharmaceutica Nv Salicylanilide derivatives
DE2557615C2 (de) 1975-12-20 1985-08-14 Bayer Ag, 5090 Leverkusen Neue Niclosamid-Suspensionsformulierungen
SU597671A1 (ru) 1976-10-07 1978-03-15 Предприятие П/Я М-5400 Способ очистки 3,4,5-трибромсалициланилида
JPS55129256A (en) 1979-02-28 1980-10-06 Isao Ozawa Antifungal compound
US4287191A (en) 1980-04-14 1981-09-01 The Research Foundation Of State University Of New York Novel salicylanilides and microbiocidal compositions and uses thereof
US4358443A (en) 1980-04-14 1982-11-09 The Research Foundation Of State University Of New York Method and composition for controlling the growth of microorganisms
US4560549A (en) 1983-08-24 1985-12-24 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4742083A (en) 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
EP0185490B1 (en) 1984-12-12 1991-09-25 Euroceltique S.A. Antibacterial cream
US4939132A (en) 1985-04-15 1990-07-03 The Research Foundation Of State University Of New York Novel 5-alkylsulfonylsalicylanilides and microbiocidal compositions for controlling the growth of microorganisms
US4883660A (en) 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
EP0487973B1 (en) 1990-11-26 1996-03-27 Bayer Corporation Topical lotion containing Niclosamide
AU4399296A (en) 1994-12-19 1996-07-10 Lauteral Limited A combination product comprising nitazoxanide and an anti-ulcer agent
EP1174439B1 (en) 1996-08-21 2008-10-08 Migenix Inc. Compositions and methods for treating infections using analogues of indolicidin
US5958911A (en) 1996-11-05 1999-09-28 The Research Foundation Of State University Of New York Method of relieving inflammation by using 5-alkylsulfonylsalicylanilides
EP0984783A1 (en) 1997-06-11 2000-03-15 Bayer Ag Anthelmintic compositions
US6117859A (en) 1997-11-04 2000-09-12 The Research Foundation Of State University Of New York Method of relieving chronic inflammation by using 5-alkylsulfonylsalicylanilides
EP1071409B1 (de) 1998-04-14 2003-10-15 BioAgency AG Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen
DE19828097A1 (de) 1998-06-24 1999-12-30 Hassan Jomaa Kombinationspräparat von Aminohydrocarbylphosphonsäurederivaten und Hemmern des Fettstoffwechsels
DE19843222A1 (de) 1998-09-22 2000-03-30 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
DE19843223A1 (de) 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
AU746606B2 (en) 1998-05-18 2002-05-02 Pharmacia & Upjohn Company Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
DE19843360A1 (de) 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
US6753324B2 (en) 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
EE200100027A (et) 1998-07-15 2002-06-17 Jomaa Hassan Fosfororgaanilised ühendid, neid sisaldav farmatseutiline preparaat ja nende kasutamine
DE19843383A1 (de) 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
DE19843334A1 (de) 1998-09-22 2000-03-30 Hassan Jomaa Schwefelorganische Verbindungen und ihre Verwendung
DE19854403A1 (de) 1998-11-25 2000-05-31 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
DE19859426A1 (de) 1998-12-22 2000-07-06 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
DE19902924A1 (de) 1999-01-26 2000-08-03 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur prophylaktischen und therapeutischen Behandlung von Infektionen
DE19903398A1 (de) 1999-01-29 2000-08-10 Hassan Jomaa Verwendung von Thiadiazolderivaten zur prophylaktischen und therapeutischen Behandlung von Infektionen
CH693625A5 (it) 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
WO2001060157A2 (en) 2000-02-18 2001-08-23 The Procter & Gamble Company Antibacterial agents and compositions
WO2001060829A1 (de) 2000-02-18 2001-08-23 Jomaa Pharmaka Gmbh Phosphororganische verbindungen und ihre verwendung
WO2001093872A1 (de) 2000-06-08 2001-12-13 Jomaa Pharmaka Gmbh Verwendung von phosphororganischen hydroxamsäurederivaten zur herstellung von arzneimitteln
KR100864373B1 (ko) 2000-07-19 2008-10-21 유니티카 가부시끼가이샤 스핑고당지질을 함유하는 화장품 및 이의 제조방법
US6774100B2 (en) 2000-12-06 2004-08-10 Imaginative Research Associates, Inc. Anhydrous creams, lotions and gels
EA011719B1 (ru) 2000-12-18 2009-04-28 Институт Оф Медисинал Молекьюлар Дизайн, Инк. Ингибитор высвобождения воспалительного цитокина
US6830758B2 (en) 2001-04-02 2004-12-14 Lectec Corporation Psoriasis patch
US20020192273A1 (en) 2001-06-15 2002-12-19 Teri Buseman Therapeutic patch useful for the treatment of hemorrhoids
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
GB2386066A (en) 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
RU2227025C2 (ru) 2002-05-21 2004-04-20 ЗАО "Агроветсервис" Антипаразитарный препарат широкого спектра действия
WO2003103665A1 (ja) 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 抗アレルギー薬
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
AU2003260818A1 (en) 2002-11-28 2004-06-18 Moore, Bronwyn Treatment of immune system dysfunction
WO2004062600A2 (en) 2003-01-08 2004-07-29 Lectec Corporation Antiviral patch
JP4446678B2 (ja) * 2003-05-08 2010-04-07 株式会社ノエビア 抗菌剤
CN1852729A (zh) * 2003-09-16 2006-10-25 安斯泰来制药有限公司 疮疱丙酸杆菌的抗菌剂
US20070059351A1 (en) 2003-10-17 2007-03-15 Murrell George A C Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods
US7666444B2 (en) 2004-02-02 2010-02-23 Wyeth Antiparasitic composition
US8198326B2 (en) * 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
US20060222692A1 (en) 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
KR20130114229A (ko) 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 경피 약물 전달 방법 및 조성물
JP4920206B2 (ja) 2005-06-30 2012-04-18 ライオン株式会社 外用剤組成物及び貼付剤、並びに薬物の経皮吸収組成物
GB0525093D0 (en) 2005-12-09 2006-01-18 Norbrook Lab Ltd Veterinary composition
US7727513B2 (en) * 2005-12-15 2010-06-01 Kimberly-Clark Worldwide, Inc. Method for screening for bacterial conjunctivitis
US20070254036A1 (en) 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
WO2008006848A1 (en) 2006-07-13 2008-01-17 Galderma Research & Development Composition comprising a retinoid and benzoyl peroxide
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US20090016990A1 (en) 2007-01-24 2009-01-15 Alberte Randall S Antimicrobial Compositions
WO2008133982A2 (en) 2007-04-27 2008-11-06 Lectec Corporation Adhesive patch with aversive agent
GB2449973B8 (en) * 2007-05-31 2010-01-06 Syntopix Group Plc Antibacterial & anti-acne formulations containing dialkyl sulphosuccinates
GB0711957D0 (en) * 2007-06-21 2007-08-01 Syntopix Ltd Formulations
ES2324192B1 (es) * 2008-01-30 2010-06-17 PUIG BEAUTY & FASHION GROUP, S.L. Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas.
MX2010009891A (es) 2008-03-07 2011-03-04 Lectec Corp Parche desinfectante para las manos.
WO2009140215A2 (en) 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
US20100029781A1 (en) 2008-06-04 2010-02-04 Morris Jerome A Methods for preparation of anti-acne formulation and compositions prepared thereby
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
BRPI0910496A2 (pt) 2008-07-07 2016-08-02 Activ Biotics Pharma Llc aplicação de rifalazil para tratar distúrbios colônicos.
US8846646B2 (en) 2008-10-03 2014-09-30 Winlind Skincare, Llc Topical treatment of skin infection
EP2177208A1 (en) * 2008-10-17 2010-04-21 Ferrer Internacional, S.A. Pharmaceutical topical compositions
EP2369923B1 (en) 2008-11-26 2016-06-22 Viroblock SA Methods for inhibiting gram-positive bacteria using non-phospholipid lipid vesicules
GB2465633A (en) 2008-12-01 2010-06-02 Syntopix Ltd Anti-acne formulation
GB2456376A (en) * 2008-12-22 2009-07-15 Syntopix Ltd Antibacterial/anti-acne formulations comprising a halogenated salicylanilide in combination with one or more anti-acne agents
CA2761039A1 (en) 2009-05-07 2010-11-11 Tolmar, Inc. Pharmaceutical composition including a corticosteroid and a vitamin d analog having improved stability
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
US20130005802A1 (en) 2009-09-21 2013-01-03 Wei Chen Treatment of wnt/frizzled-related diseases
GB2477914B (en) 2010-02-12 2012-01-04 Univ Newcastle Compounds and methods for biofilm disruption and prevention
BRPI1002601E2 (pt) 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
FR2961810B1 (fr) * 2010-06-29 2012-07-06 Galderma Res & Dev Esters de metronidazole pour traiter la rosacee
JP5518595B2 (ja) * 2010-06-30 2014-06-11 日本エンバイロケミカルズ株式会社 工業用防腐・防汚組成物
GB201015079D0 (en) * 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
DE102010054149A1 (de) 2010-12-10 2012-06-14 Merck Patent Gmbh 2-Pyrone
ES2647072T3 (es) 2011-04-18 2017-12-19 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Niclosamida para el tratamiento de la metástasis en el cáncer
WO2012154944A2 (en) 2011-05-10 2012-11-15 Stc.Unm Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
US9034812B2 (en) 2011-08-26 2015-05-19 Ohio University Compositions and methods for treating biofilms
FR2991173B1 (fr) 2012-06-04 2015-11-06 Virbac Composition veterinaire a administration cutanee a base d'oxyclozanide
JP6398719B2 (ja) * 2012-09-26 2018-10-03 東洋製罐グループホールディングス株式会社 食中毒菌の培養培地、及び食中毒菌の検出方法
US20150250808A1 (en) 2012-10-15 2015-09-10 Vojo P. Deretic Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
AU2014214547B2 (en) 2013-02-08 2018-08-30 Luoda Pharma Limited Methods of treating topical microbial infections
CN105143176B (zh) 2013-02-15 2018-02-13 柏林工业大学 白纹黄单胞菌毒素衍生物、其用途以及合成
CN105358141A (zh) 2013-05-01 2016-02-24 尼奥酷里私人有限公司 治疗细菌感染的方法
WO2014200705A1 (en) 2013-06-14 2014-12-18 Stc.Unm Treatment of autophagy-related disorders
EP2839828A1 (en) 2013-08-23 2015-02-25 Nitto Denko Corporation Compunds and formulations for the treatment of wounds
US10059752B2 (en) 2013-10-14 2018-08-28 University Of Houston System Esculentin 1a derivatives and uses thereof
IN2013MU03583A (es) 2013-11-14 2015-07-31 Cipla Ltd
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
EP3473630B1 (en) 2014-07-02 2021-01-13 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
WO2016036839A1 (en) 2014-09-02 2016-03-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating gonorrhea
US20170258816A1 (en) * 2014-09-12 2017-09-14 Antibiotx Aps Antibacterial Use of Halogenated Salicylanilides
US20190328687A1 (en) 2014-11-17 2019-10-31 Victoria Link Limited Antibacterial Compounds
EP3020398A1 (en) 2014-11-17 2016-05-18 Nitto Denko Corporation Compounds and formulations for reducing scarring
US10213478B2 (en) 2014-11-24 2019-02-26 The Translational Genomics Research Institute Compositions and methods for the treatment of fungal infections
CN104430338B (zh) 2014-12-08 2016-08-31 江苏艾津农化有限责任公司 氯硝柳胺乙醇胺盐可湿性粉剂及其制备方法和应用
WO2016138286A1 (en) 2015-02-26 2016-09-01 Stc.Unm Irgm and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
US10406132B2 (en) 2015-03-09 2019-09-10 The Children's Mercy Hospital Dermatophytosis prophylaxis and treatment
JP2018509412A (ja) 2015-03-10 2018-04-05 イーエルシー マネージメント エルエルシー 炎症を収束させるよう皮膚を処置するための方法および組成物ならびに炎症収束経路を刺激する活性物質のスクリーニング
GB2542873A (en) 2015-04-16 2017-04-05 Elc Man Llc Unit dose packages, compositions, and treatment regimens to deliver pro-resolution pathway stimulators to keratin surfaces
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US10905665B2 (en) 2015-06-24 2021-02-02 Duke University Chemical modulators of signaling pathways and therapeutic use
WO2016210247A1 (en) 2015-06-24 2016-12-29 Duke University New methods of use for an anti-diarrhea agent
WO2017040864A1 (en) 2015-09-01 2017-03-09 First Wave Biopharma Methods and compositions for treating conditions associated with an abnormal inflammatory responses
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
GB201615693D0 (en) 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations
WO2018141063A1 (en) 2017-02-02 2018-08-09 Mcmaster University Bicarbonate as a potentiator for antimicrobial agents
US11709169B2 (en) 2017-02-07 2023-07-25 National Jewish Health Lipid abnormalities and association with atopic allergic diseases
CA3057284A1 (en) 2017-03-21 2018-09-27 Novalead Pharma Inc. Therapeutic agent for phosphodiesterase inhibition and its related disorders
GB201713653D0 (en) 2017-08-24 2017-10-11 Antibiotx As Dosage regimen
GB201805453D0 (en) 2018-04-03 2018-05-16 Antibiotx As Novel use
GB201813876D0 (en) 2018-08-24 2018-10-10 Antibiotx As Treatment
WO2020091804A1 (en) 2018-11-02 2020-05-07 UNION therapeutics A/S Treatment of inflammatory conditions
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
WO2020176067A1 (en) 2019-02-25 2020-09-03 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with h. pylori using a halogenated salicylanilide
US20210114973A1 (en) 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
JP2023520229A (ja) 2020-04-01 2023-05-16 ユニオン・セラピューティクス・アー／エス 製剤
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease

Also Published As

Publication number Publication date
US20170326160A1 (en) 2017-11-16
IL250988A0 (en) 2017-04-30
EA201790345A1 (ru) 2017-07-31
US11324761B2 (en) 2022-05-10
HK1223277A1 (zh) 2017-07-28
WO2016038035A1 (en) 2016-03-17
ES2661000T3 (es) 2018-03-27
DK3010511T3 (en) 2018-03-05
PH12017500463A1 (en) 2017-07-31
US20170258816A1 (en) 2017-09-14
US20200306271A1 (en) 2020-10-01
EP3338783C0 (en) 2024-01-24
PL3010511T3 (pl) 2018-07-31
US11285164B2 (en) 2022-03-29
JP2017529393A (ja) 2017-10-05
EP3338783A1 (en) 2018-06-27
AU2015314287B2 (en) 2019-04-18
EP3010511A1 (en) 2016-04-27
ES2970434T3 (es) 2024-05-28
CN106999505A (zh) 2017-08-01
EP3967312A1 (en) 2022-03-16
EP3338783B1 (en) 2024-01-24
US20190099433A1 (en) 2019-04-04
EA032899B1 (ru) 2019-07-31
BR112017004889A2 (pt) 2017-12-05
JP2023040096A (ja) 2023-03-22
AU2015314287A1 (en) 2017-03-30
KR20170078600A (ko) 2017-07-07
JP2021075567A (ja) 2021-05-20
EP3010511B1 (en) 2018-02-14
PH12017500463B1 (en) 2017-07-31
US20200306269A1 (en) 2020-10-01
CA2960331A1 (en) 2016-03-17
US9949988B2 (en) 2018-04-24
US11331327B2 (en) 2022-05-17
TR201802762T4 (tr) 2018-03-21
SG11201701928RA (en) 2017-04-27
US10758553B2 (en) 2020-09-01
US20200306270A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
PH12017500463A1 (en) Antibacterial use of halogenated salicylanilides
WO2015003816A3 (en) Cystobactamides
MX2018011249A (es) Composiciones topicas no acuosas que comprenden una salicilanilida halogenada.
WO2018106135A3 (en) Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
WO2015181356A8 (en) Vaccine composition against streptococcus suis infection
WO2015114666A3 (en) Treatments for resistant acne
WO2016108045A3 (en) Antimicrobial compounds, compositions and methods
EP3474861A4 (en) COMPOUNDS COMPRISING HMOS FOR THE PREVENTION AND / OR TREATMENT OF VIRAL AND / OR BACTERIAL INFECTIONS.
WO2017017631A3 (en) Antibacterial therapeutics and prophylactics
WO2012036580A3 (en) Antibacterial phage, phage peptides and methods of use thereof
EP3154584A4 (en) Compositions and methods for treating and preventing staphylococcus aureus infections
NZ724798A (en) Polymyxin derivatives as antimicrobial compounds
WO2015110969A3 (en) Nitrogen containing compounds and their use as antibacterial agents
EP3351553A4 (en) PEPTIDE OR ANALOGUE OF BROKEN OR FOLDED HELICOIDAL PEPTIDE HAVING ANTIMICROBIAL ACTIVITY AGAINST GRAM-NEGATIVE BACTERIA, AND USE THEREOF
WO2016004513A8 (en) Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
AU2018334025A1 (en) Antimicrobial composition
EP3330275A4 (en) Novel aminoglycoside antibiotic effective against multidrug-resistant bacteria
WO2015024021A3 (en) Antibacterial compounds
WO2014152437A3 (en) Methods of use for an antimicrobial peptide
EP3592349A4 (en) ADMINISTRATION OF ANTIBIOTIC COMPOUNDS FOR THE TREATMENT OF STREPTOCOCCAL INFECTIONS, FOR THE TREATMENT OF PSORIASIS
EP3612199A4 (en) COMMENSAL BACTERIA AS A NEW TREATMENT FOR DRY EYE AND SJÖGREN'S SYNDROME
PH12018500358A1 (en) Compounds for use in an antibacterial applications
WO2013041663A3 (de) Modifizierte apidaecinderivate als antibiotische peptide
EP3402506A4 (en) ANTIBACTERIAL COMPOSITION AND METHOD FOR THE TREATMENT OF STAPHYLOKOCKE INFECTIONS WITH ANTIBACTERIAL COMPOSITION